Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 4
1970 1
1971 5
1972 1
1974 1
1976 2
1978 3
1979 1
1981 1
1982 3
1983 2
1984 7
1985 3
1986 3
1987 4
1988 10
1989 13
1990 5
1991 9
1992 13
1993 16
1994 14
1995 13
1996 12
1997 18
1998 25
1999 14
2000 12
2001 14
2002 14
2003 3
2004 18
2005 15
2006 22
2007 21
2008 10
2009 16
2010 16
2011 16
2012 10
2013 13
2014 14
2015 21
2016 19
2017 20
2018 21
2019 24
2020 31
2021 29
2022 19
2023 22
2024 27
2025 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

634 results

Results by year

Filters applied: . Clear all
Page 1
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: sagara y. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Tamura K, et al. Among authors: sagara y. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047803 Clinical Trial.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Modi S, et al. Among authors: sagara y. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.
Direct Carotid Cavernous Fistulas.
Ide S, Kiyosue H, Tokuyama K, Hori Y, Sagara Y, Kubo T. Ide S, et al. Among authors: sagara y. J Neuroendovasc Ther. 2020;14(12):583-592. doi: 10.5797/jnet.ra.2020-0131. Epub 2020 Nov 25. J Neuroendovasc Ther. 2020. PMID: 37502141 Free PMC article. Review.
Reply to T.J.A. Dekker.
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Modi S, et al. Among authors: sagara y. J Clin Oncol. 2020 Oct 1;38(28):3351-3352. doi: 10.1200/JCO.20.01212. Epub 2020 Jul 13. J Clin Oncol. 2020. PMID: 32658630 No abstract available.
Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunction.
Otsuka Y, Imamura K, Oishi A, Asakawa K, Kondo T, Nakai R, Suga M, Inoue I, Sagara Y, Tsukita K, Teranaka K, Nishimura Y, Watanabe A, Umeyama K, Okushima N, Mitani K, Nagashima H, Kawakami K, Muguruma K, Tsujikawa A, Inoue H. Otsuka Y, et al. Among authors: sagara y. JCI Insight. 2024 Apr 22;9(8):e174179. doi: 10.1172/jci.insight.174179. JCI Insight. 2024. PMID: 38646933 Free PMC article.
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
Masuda H, Tanabe Y, Sakai H, Matsumoto K, Shimomura A, Doi M, Miyoshi Y, Takahashi M, Sagara Y, Tokunaga S, Iwasa T, Niikura N, Yoshimura K, Takano T, Tsurutani J. Masuda H, et al. Among authors: sagara y. Breast. 2023 Oct;71:22-28. doi: 10.1016/j.breast.2023.07.003. Epub 2023 Jul 13. Breast. 2023. PMID: 37459790 Free PMC article. Clinical Trial.
Non-cancer risks among female breast cancer survivors: a matched cohort study in Japan.
Kawamura C, Bhaskaran K, Konishi T, Sagara Y, Bando H, Shinozaki T, Nojiri S, Adomi M, Wong AYS, Tamiya N, Iwagami M. Kawamura C, et al. Among authors: sagara y. Lancet Reg Health West Pac. 2025 Mar 23;56:101519. doi: 10.1016/j.lanwpc.2025.101519. eCollection 2025 Mar. Lancet Reg Health West Pac. 2025. PMID: 40206327 Free PMC article.
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Yoshinami T, Takano Y, Ozaki Y, Kajiwara Y, Yamamoto M, Watanabe KI, Tsukabe M, Fujisawa F, Nagai SE, Shibata N, Oshiro C, Bando H, Tsunoda N, Yamagami K, Koizumi K, Takada M, Toriguchi N, Sekine N, Kawaguchi T, Saji S, Sagara Y, Morita S, Masuda N. Yoshinami T, et al. Among authors: sagara y. Breast Cancer. 2025 Jul;32(4):841-856. doi: 10.1007/s12282-025-01713-7. Epub 2025 May 20. Breast Cancer. 2025. PMID: 40392524 Free PMC article.
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.
Ueno T, Chow LWC, Han W, Huang CS, Mann GB, Morita S, Haga H, Fakhrejahani E, Kobayashi T, Bando H, Inoue K, Tokiwa M, Suwa H, Aruga T, Minamiguchi S, Yamada Y, Tanabe Y, Takada M, Yamashita T, Iwata H, Chung CF, Takahara S, Tokunaga E, Imoto S, Lee ES, Sagara Y, Kim JH, DeBoer RH, Kim HA, Lai HW, Hou MF, White M, Umeyama Y, Toi M. Ueno T, et al. Among authors: sagara y. Endocr Relat Cancer. 2025 Sep 11;32(9):e240353. doi: 10.1530/ERC-24-0353. Print 2025 Sep 1. Endocr Relat Cancer. 2025. PMID: 40888443 Free PMC article. Clinical Trial.
634 results